Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening

被引：147

作者：

Haeusler, S. F. M. ^{[1
]}

Keller, A. ^{[2
,3
]}

Chandran, P. A. ^{[1
,4
]}

Ziegler, K. ^{[1
]}

Zipp, K. ^{[1
]}

Heuer, S. ^{[1
]}

Krockenberger, M. ^{[1
]}

Engel, J. B. ^{[1
]}

Hoenig, A. ^{[1
]}

Scheffler, M. ^{[2
]}

Dietl, J. ^{[1
]}

Wischhusen, J. ^{[1
,5
]}

机构：

[1] Univ Wurzburg, Dept Obstet & Gynaecol, Sch Med, D-97080 Wurzburg, Germany

[2] Febit Biomed Gmbh, D-69120 Heidelberg, Germany

[3] Biomarker Discovery Ctr Heidelberg, D-69120 Heidelberg, Germany

[4] Univ Wurzburg, Grad Sch Life Sci, Sch Med, D-97080 Wurzburg, Germany

[5] Univ Wurzburg, Interdisciplinary Ctr Clin Res, Sch Med, D-97080 Wurzburg, Germany

来源：

BRITISH JOURNAL OF CANCER | 2010年 / 103卷 / 05期

关键词：

ovarian cancer; miRNA profiles; tumour marker screening; monitoring; MICRORNA EXPRESSION; CELLS; SERUM; DISEASE; BREAST;

D O I：

10.1038/sj.bjc.6605833

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

BACKGROUND: Screening is an unsolved problem for ovarian cancer (OvCA). As late detection is equivalent to poor prognosis, we analysed whether OvCA patients show diagnostically meaningful microRNA (miRNA) patterns in blood cells. METHODS: Blood-borne whole miRNome profiles from 24 patients with OvCA and 15 age-and sex-matched healthy controls were biostatistically evaluated. RESULTS: Student's t-test revealed 147 significantly deregulated miRNAs before and 4 after Benjamini-Hochberg adjustment. Although these included miRNAs already linked to OvCA (e. g., miR-16, miR-155), others had never before been connected to specific diseases. A bioinformatically calculated miRNA profile allowed for discrimination between blood samples of OvCA patients and healthy controls with an accuracy of >76%. When only cancers of the serous subtype were considered and compared with an extended control group (n=39), accuracy, specificity and sensitivity all increased to >85%. CONCLUSION: Our proof-of-principle study strengthens the hypothesis that neoplastic diseases generate characteristic miRNA fingerprints in blood cells. Still, the obtained OvCA-associated miRNA pattern is not yet sensitive and specific enough to permit the monitoring of disease progression or even preventive screening. Microarray-based miRNA profiling from peripheral blood could thus be combined with other markers to improve the notoriously difficult but important screening for OvCA. British Journal of Cancer (2010) 103, 693-700. doi:10.1038/sj.bjc.6605833 www.bjcancer.com Published online 3 August 2010 (C) 2010 Cancer Research UK

引用

页码：693 / 700

页数：8

共 46 条

[1]

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:: A combined analysis of 22 studies [J].

Antoniou, A ;

Pharoah, PDP ;

Narod, S ;

Risch, HA ;

Eyfjord, JE ;

Hopper, JL ;

Loman, N ;

Olsson, H ;

Johannsson, O ;

Borg, Å ;

Pasini, B ;

Radice, P ;

Manoukian, S ;

Eccles, DM ;

Tang, N ;

Olah, E ;

Anton-Culver, H ;

Warner, E ;

Lubinski, J ;

Gronwald, J ;

Gorski, B ;

Tulinius, H ;

Thorlacius, S ;

Eerola, H ;

Nevanlinna, H ;

Syrjäkoski, K ;

Kallioniemi, OP ;

Thompson, D ;

Evans, C ;

Peto, J ;

Lalloo, F ;

Evans, DG ;

Easton, DF .

AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 72 (05) :1117-1130

[2]

The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions [J].

Antoniou, A. C. ;

Cunningham, A. P. ;

Peto, J. ;

Evans, D. G. ;

Lalloo, F. ;

Narod, S. A. ;

Risch, H. A. ;

Eyfjord, J. E. ;

Hopper, J. L. ;

Southey, M. C. ;

Olsson, H. ;

Johannsson, O. ;

Borg, A. ;

Passini, B. ;

Radice, P. ;

Manoukian, S. ;

Eccles, D. M. ;

Tang, N. ;

Olah, E. ;

Anton-Culver, H. ;

Warner, E. ;

Lubinski, J. ;

Gronwald, J. ;

Gorski, B. ;

Tryggvadottir, L. ;

Syrjakoski, K. ;

Kallioniemi, O-P ;

Eerola, H. ;

Nevanlinna, H. ;

Pharoah, P. D. P. ;

Easton, D. F. .

BRITISH JOURNAL OF CANCER, 2008, 98 (08) :1457-1466

[3]

Early detection of ovarian cancer [J].

Badgwell, Donna ;

Bast, Robert C., Jr. .

DISEASE MARKERS, 2007, 23 (5-6) :397-410

[4]

A RADIOIMMUNOASSAY USING A MONOCLONAL-ANTIBODY TO MONITOR THE COURSE OF EPITHELIAL OVARIAN-CANCER [J].

BAST, RC ;

KLUG, TL ;

STJOHN, E ;

JENISON, E ;

NILOFF, JM ;

LAZARUS, H ;

BERKOWITZ, RS ;

LEAVITT, T ;

GRIFFITHS, CT ;

PARKER, L ;

ZURAWSKI, VR ;

KNAPP, RC .

NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (15) :883-887

[5]

MicroRNA signatures in human cancers [J].

Calin, George A. ;

Croce, Carlo M. .

NATURE REVIEWS CANCER, 2006, 6 (11) :857-866

[6]

Screening for Ovarian Cancer [J].

Clarke-Pearson, Daniel L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (02) :170-177

[7]

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival [J].

Curiel, TJ ;

Coukos, G ;

Zou, LH ;

Alvarez, X ;

Cheng, P ;

Mottram, P ;

Evdemon-Hogan, M ;

Conejo-Garcia, JR ;

Zhang, L ;

Burow, M ;

Zhu, Y ;

Wei, S ;

Kryczek, I ;

Daniel, B ;

Gordon, A ;

Myers, L ;

Lackner, A ;

Disis, ML ;

Knutson, KL ;

Chen, LP ;

Zou, WP .

NATURE MEDICINE, 2004, 10 (09) :942-949

[8]

CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use [J].

Duffy, MJ ;

Bonfrer, JM ;

Kulpa, J ;

Rustin, GJS ;

Soletormos, G ;

Torre, GC ;

Tuxen, MK ;

Zwirner, M .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2005, 15 (05) :679-691

[9]

Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients [J].

Eisenhauer, EA ;

Vermorken, JB ;

vanGlabbeke, M .

ANNALS OF ONCOLOGY, 1997, 8 (10) :963-968

[10]

Serum MicroRNAs Are Promising Novel Biomarkers [J].

Gilad, Shlomit ;

Meiri, Eti ;

Yogev, Yariv ;

Benjamin, Sima ;

Lebanony, Danit ;

Yerushalmi, Noga ;

Benjamin, Hila ;

Kushnir, Michal ;

Cholakh, Hila ;

Melamed, Nir ;

Bentwich, Zvi ;

Hod, Moshe ;

Goren, Yaron ;

Chajut, Ayelet .

PLOS ONE, 2008, 3 (09)

← 1 2 3 4 5 →